Download the ESMO 2012 Abstract Book - Oxford Journals

Annals of Oncology
7.4% myeloma. Of those patients with solid tumours, 30.1% of patients had a stage III
and 21.6% had a stage IV tumour. Almost all patients received the biosimilar epoetin
zeta (Retacrit®, Hospira UK Ltd., median dose 30,000 IU/week). Mean baseline Hb
level across all patients was 9.6 g/dL, with 35.6% of patients having moderate anaemia
(Hb 8–9.5 g/dL). Following treatment, Hb response was achieved in 81.6% and 86.5%
of patients at 3 and 6 months, respectively. The overall mean change in Hb level was
1.5 ± 1.6 g/dL at 3 months and 1.72 ± 1.61 g/dL at 6 months. Transfusion rates were
9.4% and 5.8%, while the rate of thromboembolic events was 2.4% and 1.5%, at 3 and
6 months respectively. In conclusion, Retacrit was effective and well tolerated in the
management of CIA in patients with solid tumours, lymphoma and myeloma.
Disclosure: M. Michallet: I received honoraria from Hospira for advisory boards and
consulting, P. Soubeyran: I received honoraria from Hospira for advisory boards and
consulting, H. Albrand: Employed by Hospira, E. Luporsi: I received honoraria from
Hospira for advisory boards and consulting.
1564P ANAEMIA-RELATED FATIGUE IN PATIENTS WITH SOLID
TUMOURS: A MULTICENTER, OBSERVATIONAL AND
PROSPECTIVE STUDY (PACS STUDY)
P. Gascon 1 , A. Casas 2 , J. Muñoz 3 , J. De Castro 4 , V. Alberola 5 , M. Cucala 6 and
F. Barón 7
1 Medical Oncology, Hospital Clinic y Provincial de Barcelona, Barcelona, SPAIN,
2 Medical Onology Department, Hospital Virgen del Rocío, Sevilla, SPAIN,
3 Medical Oncology Department, Hospital Dr. Peset, Valencia, SPAIN, 4 Medical
Oncology Department, Hospital La Paz, Madrid, SPAIN, 5 Medical Oncology
Department, Hospital Arnau de Vilanova, Valencia, SPAIN, 6 Medical Advisor,
Vifor Pharma España, Barcelona, SPAIN, 7 Medical Oncology Department,
Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de
Compostela, SPAIN
Background: Quality of life in cancer patients is significantly reduced by anaemia
and associated fatigue. Fatigue is one of the most common symptoms of cancer
and cancer therapy. The aim of the present study was to evaluate fatigue in
treatment-naive patients with solid tumours and after four months of cancer
therapy using the Functional Assessment of Cancer Therapy-Fatigue (FACT-F)
questionnaire.
Methods: Multicenter, prospective and observational study that included newly
diagnosed cancer patients. Patients completed the FACT-F questionnaire at
baseline and after four months of cancer therapy. Anaemia status (haemoglobin